Clinical trials: Seborrheic Dermatitis
Seborrheic Dermatitis
Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
This was a parallel group, double blind, vehicle-controlled study assessed the safety and efficacy of roflumilast foam (ARQ-154) vs placebo foam in participants with seborrheic dermatitis.
- Trial name
- NCT04091646
- Testing
- Roflumilast Foam 0.3%, Vehicle foam
- Where
- 24 sites in United States, Canada
- Volunteers
- 226 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Dermatitis, Seborrheic, Dry Skin; Eczema
Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult
The purpose of this study is to evaluate the safety and efficacy of a novel topical treatment for dry scalp conditions, including dandruff, seborrheic dermatitis, and atopic dermatitis.
- Trial name
- NCT03830177
- Testing
- Natural Treatment
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Scalp Seborrheic Dermatitis
Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis
The objective is to assess different treatment regimens with Clobetasol propionate shampoo 0.05% in the treatment of scalp Seborrheic Dermatitis.
- Trial name
- Escape (NCT00862654)
- Where
- 18 sites in Belgium, France and 3 more
- Volunteers
- 326 people
- Sponsor
- Galderma R&D
Seborrheic Dermatitis
Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo
The aims of this study are to compare the effectiveness of antifungal foam versus antifungal shampoo and determine patient compliance and satisfaction with both vehicles among African American females with dandruff practicing…
- Trial name
- NCT01203189
- Testing
- ketoconazole 2% foam
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- St. Louis University
Seborrheic Dermatitis
Ruxolitinib in Seborrheic Dermatitis
This study is an open-label prospective interventional trial that will assess the efficacy of ruxolitinib in the treatment of seborrheic dermatitis.
- Trial name
- NCT05787860
- Testing
- Ruxolitinib 1.5% Cream
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Seborrheic Dermatitis
A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
Seborrheic dermatitis is a common and recurrent dermatosis that characteristically involves the scalp, nasolabial folds, eyebrows, glabella, and upper eye lids.
- Trial name
- NCT03567980
- Testing
- Crisaborole
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Hirsutism, Androgenetic Alopecia
DUS on the Prescribing Indications for CPA/EE in 5 European Countries
This study was designed to compile the reasons and specific indications for the prescription of Cyproterone Acetate combined with Ethinyl Estradiol by Health Care Providers.
- Conditions
- Hirsutism, Androgenetic Alopecia, Severe Anemia, Seborrhea
- Trial name
- NCT02494297
- Where
- Germany
- Volunteers
- 1,597 people, healthy volunteers welcome
- Sponsor
- Center for Epidemiology and Health Research, Germany
Dermatitis, Seborrheic
STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%
Extina (ketoconazole) Foam, 2% was approved for marketing in the United States (US) in June 2007. Extina foam is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older.
- Trial name
- NCT00703846
- Testing
- Ketoconazole
- Volunteers
- 498 people
- Sponsor
- Stiefel, a GSK Company
Seborrheic Dermatitis
A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
This is an exploratory study to determine effectiveness of Elidel for the treatment of seborrheic dermatitis
- Trial name
- NCT00403559
- Testing
- Elidel, Ketoconazole Cream
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Dermatology Specialists Research
Cradle Cap, Infantile Seborrheic Dermatitis
Promiseb Topical Cream for Cradle Cap
The purpose of this study is to evaluate the efficacy and safety of Promiseb Topical Cream in cradle cap.
- Trial name
- NCT01214434
- Testing
- Promiseb Topical Cream, Bland emollient
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Promius Pharma, LLC
Seborrheic Dermatitis
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
This phase 3, double-blind, vehicle-controlled study assessed the safety and efficacy of roflumilast (ARQ-154) foam 0.3% applied once daily (qd) for 8 weeks by participants with seborrheic dermatitis.
- Trial name
- NCT04973228
- Testing
- Roflumilast Foam, Vehicle Foam
- Where
- 53 sites in United States, Canada
- Volunteers
- 457 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Dandruff, Seborrheic Dermatitis
Cleansing Device for the Treatment of Scalp and Hair Conditions
The objective of this study is to evaluate an improvement of scalp health after the use of an investigational off-label WaterPik and brush device aimed to massage and cleanse the scalp.
- Conditions
- Dandruff, Seborrheic Dermatitis, Hair Loss
- Trial name
- NCT05319444
- Testing
- Off-brand Waterpik®
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Seborrheic Dermatitis
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
This is an open-label, long-term safety study of roflumilast ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving up to 20% total Body Surface Area (BSA). Study was applied topically once daily for 52 weeks.
- Trial name
- NCT04445987
- Testing
- ARQ-154
- Where
- 39 sites in United States
- Volunteers
- 408 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Parkinson Disease
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
The major purpose of this study is to assess the efficacy of CBD on motor symptoms of Parkinson's Disease (PD), and secondarily to study the safety and tolerability of CBD and other efficacy, particularly regarding tremor in PD.
- Trial name
- NCT03582137
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Colorado, Denver
Seborrheic Dermatitis, Papulopustular Rosacea
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
This study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai.
- Trial name
- NCT06013371
- Testing
- PF-07038124
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Icahn School of Medicine at Mount Sinai